Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?
Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Cognetti(Apple (Israel)), Alessandra Fabi(Agostino Gemelli University Polyclinic), Enzo Maria Ruggeri, Paolo Carlini(National Cancer Institute), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), C. Nardoni(Cancer Institute (WIA)), Andrea Alimonti(Veneto Institute of Molecular Medicine), Paola Papaldo(Cancer Institute (WIA))
Cited by 7
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Cellular Senescence: Aging, Cancer, and Injury
|Physiological Reviews|2019|1.3k
Subtle variations in Pten dose determine cancer susceptibility
|Nature Genetics|2010|579